Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

21.

The 21st Century Cures Act--Will It Take Us Back in Time?

N. Engl. J. Med.
Avorn J, Kesselheim AS.
| Jun 25, 2015
22.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

N. Engl. J. Med.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Musliner T.
| Jun 18, 2015
23.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

N. Engl. J. Med.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P.
| Jun 2, 2015
24.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

N. Engl. J. Med.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR.
| Jul 9, 2015
25.

The good merger.

N. Engl. J. Med.
Dafny LS, Lee TH.
| May 28, 2015
26.

ClinGen--the Clinical Genome Resource.

N. Engl. J. Med.
Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS, Andersen E.
| Jun 4, 2015
27.

Trial of short-course antimicrobial therapy for intraabdominal infection.

N. Engl. J. Med.
Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, Cook CH, O'Neill PJ, Mazuski JE, Askari R, Wilson MA, Napolitano LM, Namias N, Miller PR, Dellinger EP, Watson CM, Coimbra R, Dent DL, Lowry SF, Cocanour CS, West MA, Banton KL, Cheadle WG, Lipsett PA, Guidry CA, Popovsky K.
| May 21, 2015
28.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

N. Engl. J. Med.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, Tran B.
| May 14, 2015
29.

The $2.6 billion pill--methodologic and policy considerations.

N. Engl. J. Med.
Avorn J.
| May 14, 2015
30.

A longitudinal study of bullying of sexual-minority youth.

N. Engl. J. Med.
Schuster MA, Bogart LM, Elliott MN, Klein DJ, Feng JY, Tortolero SR, Mrug S, Lewis TH.
| May 7, 2015
31.

Lessons in medicine, mortality, and reflexive verbs.

N. Engl. J. Med.
Schoenthaler R.
| May 7, 2015
32.

Progress and Hurdles for Follow-on Biologics.

N. Engl. J. Med.
Sarpatwari A, Avorn J, Kesselheim AS.
| Jun 18, 2015
33.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N. Engl. J. Med.
Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.
| Apr 30, 2015
34.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N. Engl. J. Med.
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.
| Apr 30, 2015
35.

Why strategy matters now.

N. Engl. J. Med.
Porter ME, Lee TH.
| Apr 30, 2015
36.

Getting the right medical students--nature versus nurture.

N. Engl. J. Med.
Schwartzstein RM.
| Apr 23, 2015
37.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

N. Engl. J. Med.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.
| May 21, 2015
38.

Tuberculosis among the homeless--preventing another outbreak through community action.

N. Engl. J. Med.
Gupta V, Sugg N, Butners M, Allen-White G, Molnar A.
| Apr 16, 2015
39.

Performance differences in year 1 of pioneer accountable care organizations.

N. Engl. J. Med.
McWilliams JM, Chernew ME, Landon BE, Schwartz AL.
| May 14, 2015
40.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

N. Engl. J. Med.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.
| Apr 9, 2015